Affiliation: Liaoning Medical University, China
Journal Associated: Journal of Genetic Medicine and Gene Therapy
Xia pu, PhD, earned bachelor’s degrees in Clinical Medicine from Hebei Medical University, and a PhD in Biochemistry and Molecular Biology from China Medical University. He is a member of European Academy of Tumor Immunology (EATI). He currently works as an assistant professor at Liaoning Medical University. He has published fifteen articles as first author or corresponding author in internationally known medical journals: oncotarget, apoptosis, Am J Cancer Res, tumor biology, and Cell Prolif. In his current work, he hope to promote NK cells-based CSCs immunotherapy to be used in clinic.
The long-term goal of our research program is to isolate cancer stem-like cells and understand the molecular mechanisms of these cells. In order to find a novel prognostic marker for cancer patients, I and my colleagues firstly carried out bioinformatic analyses (Xia et al. Oncotarget 2016). Then we will perform the following researches:
(1) Isolation of cancer stem-like cells. In our previous studies, we isolated circulating cancer stem-like cells from the peripheral blood of these patients by using CD133, CD44 or ALDH1. The correlation between circulating CD133+ cells and the survival rate of the patients with gastric cancer has been confirmed by our team (Xia et al. Cell Prolif 2015; Wang et al. Tumour Biol 2016).
(2) Tumorigenecity of isolated cancer stem-like cells. I and my colleagues determined the roles and the molecular mechanisms of these cells both in vivo and in vitro (Xia et al. Oncol Rep 2013; Xia et al. Cancer Biother Radiopharm 2013).
(3) Potential therapy on cancer stem-like cells. In our previous studies, we have confirmed the anti-tumor roles of PDCD5, Trail, and DKK3 in cancer stem-like cells (Xu et al. Cell cycle 2012; Xia et al. Apoptosis 2014; Wang et al. Tumour Biol 2016). In one of our recent studies, we found the cytotoxic effect of natural killer cells on CD133+ gastric cancer cells. We hope to promote NK cells-based CSCs immunotherapy to be used in clinic.